

Matthew R Weir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1830663/publications.pdf>

Version: 2024-02-01

510
papers

25,900
citations

5574

82
h-index

9861

141
g-index

516
all docs

516
docs citations

516
times ranked

20387
citing authors

#	ARTICLE	IF	CITATIONS
1	Angiotensin-Converting Enzyme Inhibitor-Associated Elevations in Serum Creatinine. Archives of Internal Medicine, 2000, 160, 685-93.	3.8	679
2	MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nature Genetics, 2008, 40, 1185-1192.	21.4	587
3	Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. New England Journal of Medicine, 2015, 372, 211-221.	27.0	521
4	The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease. Archives of Internal Medicine, 2009, 169, 1156.	3.8	501
5	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet, The, 2010, 375, 1173-1181.	13.7	472
6	Effects of Blood Pressure Level on Progression of Diabetic Nephropathy<sub>title>Results From the RENAAL Study</sub>. Archives of Internal Medicine, 2003, 163, 1555.	3.8	399
7	Clinical Course of Polyoma Virus Nephropathy in 67 Renal Transplant Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 2145-2151.	6.1	398
8	Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease. JAMA - Journal of the American Medical Association, 2015, 314, 151.	7.4	370
9	Cell-Free DNA and Active Rejection in Kidney Allografts. Journal of the American Society of Nephrology: JASN, 2017, 28, 2221-2232.	6.1	365
10	Risk for posttransplant diabetes mellitus with current immunosuppressive medications. American Journal of Kidney Diseases, 1999, 34, 1-13.	1.9	363
11	Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib. Circulation, 2001, 104, 2280-2288.	1.6	353
12	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. Journal of the American College of Cardiology, 2012, 60, 434-480.	2.8	328
13	A Prospective Controlled Study of Kidney Donors: Baseline and 6-Month Follow-up. American Journal of Kidney Diseases, 2013, 62, 577-586.	1.9	323
14	Hypertension Awareness, Treatment, and Control in Adults With CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2010, 55, 441-451.	1.9	320
15	ISLET CELL DAMAGE ASSOCIATED WITH TACROLIMUS AND CYCLOSPORINE: MORPHOLOGICAL FEATURES IN PANCREAS ALLOGRAFT BIOPSIES AND CLINICAL CORRELATION1. Transplantation, 1999, 68, 396-402.	1.0	298
16	Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2007, 18, 1540-1546.	6.1	280
17	Microalbuminuria and Cardiovascular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 581-590.	4.5	277
18	Hypertension in CKD: Core Curriculum 2019. American Journal of Kidney Diseases, 2019, 74, 120-131.	1.9	277

#	ARTICLE	IF	CITATIONS
19	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	5.2	260
20	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. <i>Circulation</i> , 2012, 126, 617-663.	1.6	255
21	Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. <i>Kidney International</i> , 1998, 54, 1283-1289.	5.2	246
22	Human polyoma virus in renal allograft biopsies: Morphological findings and correlation with urine cytology. <i>Human Pathology</i> , 1999, 30, 970-977.	2.0	243
23	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. <i>Endocrine Practice</i> , 2016, 22, 753-762.	2.1	242
24	Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2198-2205.	2.8	240
25	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	5.2	232
26	Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1051-1060.	2.8	225
27	Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1678.	7.4	217
28	Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 77-85.	2.8	215
29	A COMPARISON OF RECIPIENT RENAL OUTCOMES WITH LAPAROSCOPIC VERSUS OPEN LIVE DONOR NEPHRECTOMY. <i>Transplantation</i> , 1999, 67, 722-728.	1.0	214
30	Estimating GFR Among Participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2012, 60, 250-261.	1.9	207
31	Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 531-548.	4.5	196
32	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2021, 99, 34-47.	5.2	195
33	Aortic PWV in Chronic Kidney Disease: A CRIC Ancillary Study. <i>American Journal of Hypertension</i> , 2010, 23, 282-289.	2.0	192
34	Differential effects of calcium antagonist subclasses on markers of nephropathy progression. <i>Kidney International</i> , 2004, 65, 1991-2002.	5.2	189
35	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	2.2	186
36	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 201-213.	1.9	174

#	ARTICLE	IF	CITATIONS
37	Urinary Sodium and Potassium Excretion and CKD Progression. Journal of the American Society of Nephrology: JASN, 2016, 27, 1202-1212.	6.1	174
38	Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients. Circulation, 2011, 123, 1763-1770.	1.6	171
39	Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney International, 2001, 59, 1567-1573.	5.2	166
40	Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney International, 2011, 79, 897-907.	5.2	164
41	Masked Hypertension and Elevated Nighttime Blood Pressure in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 642-652.	4.5	157
42	Effects of renin-angiotensin system inhibition end-organ protection: Can we do better?. Clinical Therapeutics, 2007, 29, 1803-1824.	2.5	152
43	Morphological Spectrum of Polyoma Virus Disease in Renal Allografts: Diagnostic Accuracy of Urine Cytology. American Journal of Transplantation, 2001, 1, 373-381.	4.7	146
44	Extravascular Lung Water Assessment by Ultrasound to Guide Dry Weight Changes: Ready for Prime Time?. American Journal of Kidney Diseases, 2020, 75, 1-3.	1.9	144
45	Current status of kidney and pancreas transplantation in the United States, 1994-2003. American Journal of Transplantation, 2005, 5, 904-915.	4.7	143
46	A Prospective Controlled Study of Living Kidney Donors: Three-Year Follow-up. American Journal of Kidney Diseases, 2015, 66, 114-124.	1.9	142
47	A NOVEL APPROACH TO THE TREATMENT OF CHRONIC ALLOGRAFT NEPHROPATHY1. Transplantation, 1997, 64, 1706-1710.	1.0	140
48	Assessment and Management of Hypertension in Transplant Patients. Journal of the American Society of Nephrology: JASN, 2015, 26, 1248-1260.	6.1	138
49	Dry-Weight. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1255-1260.	4.5	137
50	Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney International, 2008, 74, 364-369.	5.2	135
51	Assessment and Management of Hypertension in Patients on Dialysis. Journal of the American Society of Nephrology: JASN, 2014, 25, 1630-1646.	6.1	134
52	Effect of patiomer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. European Journal of Heart Failure, 2015, 17, 1057-1065.	7.1	134
53	Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease. Hypertension, 2016, 67, 387-396.	2.7	134
54	Lisinopril Versus Hydrochlorothiazide in Obese Hypertensive Patients. Hypertension, 1997, 30, 140-145.	2.7	133

#	ARTICLE	IF	CITATIONS
55	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet, The</i> , 2013, 381, 537-545.	13.7	132
56	Insulin Resistance, Elevated Glomerular Filtration Fraction, and Renal Injury. <i>Hypertension</i> , 1996, 28, 127-132.	2.7	131
57	Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2015, 162, 258-265.	3.9	128
58	Novel RAAS agonists and antagonists: clinical applications and controversies. <i>Nature Reviews Endocrinology</i> , 2015, 11, 242-252.	9.6	126
59	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 861-876.	5.2	126
60	Influence of Race and Dietary Salt on the Antihypertensive Efficacy of an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Antagonist in Salt-Sensitive Hypertensives. <i>Hypertension</i> , 1998, 31, 1088-1096.	2.7	124
61	Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. <i>American Heart Journal</i> , 2003, 146, 591-604.	2.7	122
62	Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. <i>American Journal of Nephrology</i> , 2016, 43, 229-236.	3.1	117
63	Equivalent Success of Simultaneous Pancreas Kidney and Solitary Pancreas Transplantation. <i>Annals of Surgery</i> , 1996, 224, 440-452.	4.2	117
64	EVALUATION OF PANCREAS TRANSPLANT NEEDLE BIOPSY. <i>Transplantation</i> , 1997, 63, 1579-1586.	1.0	115
65	Differing Mechanisms of Action of Angiotensin-Converting Enzyme Inhibition in Black and White Hypertensive Patients. <i>Hypertension</i> , 1995, 26, 124-130.	2.7	113
66	Development and validation of GFR-estimating equations using diabetes, transplant and weight. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 449-457.	0.7	111
67	Characterization and implications of the initial estimated glomerular filtration rate \hat{eGFR}^{TM} upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021, 99, 750-762.	5.2	111
68	A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. <i>Transplantation</i> , 2016, 100, 184-193.	1.0	110
69	The genetic response to short-term interventions affecting cardiovascular function: Rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. <i>American Heart Journal</i> , 2008, 155, 823-828.	2.7	109
70	Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. <i>Hepatology</i> , 2014, 59, 1532-1542.	7.3	108
71	An In-Depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2006, 26, 268-275.	3.1	105
72	Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality. <i>Hypertension</i> , 2018, 71, 1101-1107.	2.7	99

#	ARTICLE	IF	CITATIONS
73	Variability of Creatinine Measurements in Clinical Laboratories: Results from the CRIC Study. <i>American Journal of Nephrology</i> , 2010, 31, 426-434.	3.1	97
74	Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2014, 16, 875-882.	2.0	95
75	Implications of a Health Lifestyle and Medication Analysis for Improving Hypertension Control. <i>Archives of Internal Medicine</i> , 2000, 160, 481.	3.8	94
76	Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). <i>Current Medical Research and Opinion</i> , 2014, 30, 1759-1768.	1.9	94
77	Abnormalities of Potassium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2836-2850.	2.8	94
78	Salt-Induced Increases in Systolic Blood Pressure Affect Renal Hemodynamics and Proteinuria. <i>Hypertension</i> , 1995, 25, 1339-1344.	2.7	93
79	DOUBLE RENAL ALLOGRAFTS SUCCESSFULLY INCREASE UTILIZATION OF KIDNEYS FROM OLDER DONORS WITHIN A SINGLE ORGAN PROCUREMENT ORGANIZATION. <i>Transplantation</i> , 1996, 62, 1581-1583.	1.0	92
80	Patiomer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. <i>Kidney International</i> , 2015, 88, 1427-1433.	5.2	90
81	Double adult renal allografts: A technique for expansion of the cadaveric kidney donor pool. <i>Surgery</i> , 1996, 120, 580-584.	1.9	89
82	Plant Protein Intake is Associated With Fibroblast Growth Factor 23 and Serum Bicarbonate Levels in Patients With Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study. , 2012, 22, 379-388.e1.		88
83	High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. <i>American Journal of Transplantation</i> , 2020, 20, 2491-2498.	4.7	87
84	Clinical Management of Hyperkalemia. <i>Mayo Clinic Proceedings</i> , 2021, 96, 744-762.	3.0	87
85	Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. <i>Journal of the American Society of Hypertension</i> , 2007, 1, 264-277.	2.3	86
86	Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. <i>Arthritis and Rheumatism</i> , 2008, 58, 2874-2881.	6.7	86
87	Angiotensin-Converting Enzyme Inhibitors. <i>Journal of Clinical Hypertension</i> , 2011, 13, 667-675.	2.0	83
88	Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed-Dose Combination Approaches. <i>Journal of Clinical Hypertension</i> , 2003, 5, 202-209.	2.0	82
89	Retransplantation in patients with graft loss caused by polyoma virus nephropathy. <i>Transplantation</i> , 2004, 77, 131-133.	1.0	81
90	Pancreas allograft biopsy: safety of percutaneous biopsy???results of a large experience. <i>Transplantation</i> , 2002, 73, 553-555.	1.0	81

#	ARTICLE	IF	CITATIONS
91	Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment. <i>American Heart Journal</i> , 1995, 130, 359-366.	2.7	79
92	Salt intake and progression of chronic kidney disease: An overlooked modifiable exposure? A commentary. <i>American Journal of Kidney Diseases</i> , 2005, 45, 176-188.	1.9	79
93	ACUTE EFFECTS OF INTRAVENOUS CYCLOSPORINE ON BLOOD PRESSURE, RENAL HEMODYNAMICS, AND URINE PROSTAGLANDIN PRODUCTION OF HEALTHY HUMANS. <i>Transplantation</i> , 1990, 49, 41-47.	1.0	78
94	Significance of the banff borderline biopsy. <i>American Journal of Kidney Diseases</i> , 1996, 28, 585-588.	1.9	77
95	Increased living donor volunteer rates with a formal recipient family education program. <i>American Journal of Kidney Diseases</i> , 1997, 29, 739-745.	1.9	77
96	Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , 2019, 96, 489-504.	5.2	77
97	Genotype-based changes in serum uric acid affect blood pressure. <i>Kidney International</i> , 2012, 81, 502-507.	5.2	75
98	Renal effects of nonselective NSAIDs and coxibs.. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, S153-S153.	1.3	74
99	A Titrate-to-Goal Study of Switching Patients Uncontrolled on Antihypertensive Monotherapy to Fixed-Dose Combinations of Amlodipine and Olmesartan Medoxomil ± Hydrochlorothiazide. <i>Journal of Clinical Hypertension</i> , 2011, 13, 404-412.	2.0	73
100	ISOLATED PANCREAS REJECTION IN COMBINED KIDNEY PANCREAS TRANSPLANTATION. <i>Transplantation</i> , 1996, 61, 974-977.	1.0	73
101	Efficacy and Safety of Carvedilol in Treatment of Heart Failure with Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2011, 4, 18-26.	3.9	70
102	Cardiovascular risk assessment in kidney transplantation. <i>Kidney International</i> , 2015, 87, 527-534.	5.2	70
103	Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD. <i>American Journal of Kidney Diseases</i> , 2016, 68, 892-900.	1.9	70
104	Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. <i>American Journal of Kidney Diseases</i> , 2018, 72, 873-884.	1.9	70
105	Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. <i>Kidney International Reports</i> , 2016, 1, 256-268.	0.8	69
106	Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 235-244.	1.9	68
107	HISTOLOGIC GRADING OF ACUTE ALLOGRAFT REJECTION IN PANCREAS NEEDLE BIOPSY. <i>Transplantation</i> , 1998, 66, 1741-1745.	1.0	68
108	Predictors of Compliance with Antihypertensive Therapy in a High-Risk Medicaid Population. <i>Journal of the National Medical Association</i> , 2009, 101, 34-39.	0.8	66

#	ARTICLE	IF	CITATIONS
109	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , 2007, 16, 13-19.	1.5	65
110	Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2691-2700.	2.8	65
111	Risk Factors for CKD Progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 648-659.	4.5	65
112	Treatment of Hypertension in the Very Elderly: a Clinician's Point of View. <i>Journal of Clinical Hypertension</i> , 2003, 5, 330-335.	2.0	64
113	THE PROGNOSTIC VALUE OF THE EOSINOPHIL IN ACUTE RENAL ALLOGRAFT REJECTION. <i>Transplantation</i> , 1986, 41, 709-712.	1.0	63
114	RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. <i>Current Hypertension Reports</i> , 2003, 5, 408-417.	3.5	63
115	Polyomavirus nephropathy in native kidneys of a solitary pancreas transplant recipient. <i>Transplantation</i> , 2002, 73, 1350-1353.	1.0	62
116	Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects. <i>Archives of Internal Medicine</i> , 2005, 165, 181.	3.8	62
117	APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale. <i>Kidney International Reports</i> , 2020, 5, 278-288.	0.8	62
118	BK Virus-Associated Nephropathy in Renal Allograft Recipients: Rescue Therapy by Sirolimus-Based Immunosuppression. <i>Transplantation</i> , 2004, 78, 1069-1073.	1.0	61
119	A Study of Renal Outcomes in Obese Living Kidney Donors. <i>Transplantation</i> , 2010, 90, 993-999.	1.0	60
120	The Evolving Role of mTOR Inhibition in Transplantation Tolerance. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 408-415.	6.1	60
121	BP, Cardiovascular Disease, and Death in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1554-1562.	6.1	60
122	The Association of Sleep Duration and Quality with CKD Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3708-3715.	6.1	59
123	Measured GFR Does Not Outperform Estimated GFR in Predicting CKD-related Complications. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1931-1937.	6.1	58
124	Urine Neutrophil Gelatinase-Associated Lipocalin and Risk of Cardiovascular Disease and Death in CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 267-274.	1.9	58
125	Late Calcineurin Inhibitor Withdrawal as a Strategy to Prevent Graft Loss in Patients with Suboptimal Kidney Transplant Function. <i>American Journal of Nephrology</i> , 2004, 24, 379-386.	3.1	57
126	Microalbuminuria in Type 2 Diabetics: An Important, Overlooked Cardiovascular Risk Factor. <i>Journal of Clinical Hypertension</i> , 2004, 6, 134-143.	2.0	57

#	ARTICLE	IF	CITATIONS
127	Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. <i>Kidney International</i> , 2011, 80, 288-294.	5.2	57
128	The Independent Association Between Serum Uric Acid and Graft Outcomes After Kidney Transplantation. <i>Transplantation</i> , 2010, 89, 573-579.	1.0	56
129	Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. <i>American Journal of Medicine</i> , 2013, 126, 501-508.	1.5	56
130	Drug interactions in transplant patients: what everyone should know. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 404-411.	2.0	55
131	Acute Kidney Injury and Cardiovascular Outcomes in Acute Severe Hypertension. <i>Circulation</i> , 2010, 121, 2183-2191.	1.6	55
132	Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorothiazide on 24-Hour Ambulatory Systolic Blood Pressure Control. <i>Hypertension</i> , 2011, 57, 174-179.	2.7	55
133	Treatment with patiomer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. <i>Kidney International</i> , 2016, 90, 696-704.	5.2	55
134	Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. <i>Kidney International</i> , 2022, 101, 793-803.	5.2	55
135	Preemptive Renal Transplantation: Why Not?. <i>American Journal of Transplantation</i> , 2003, 3, 1336-1340.	4.7	54
136	Cigarette Smoking and Incident Chronic Kidney Disease: A Systematic Review. <i>American Journal of Nephrology</i> , 2007, 27, 342-351.	3.1	53
137	The REDUCE HTN: REINFORCE. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 461-470.	2.9	53
138	Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2017, 70, 337-346.	1.9	52
139	Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. <i>Clinical Therapeutics</i> , 1996, 18, 411-428.	2.5	51
140	REGULATION OF THE EPITHELIAL CELL-SPECIFIC INTEGRIN, CD103, BY HUMAN CD8+ CYTOLYTIC T LYMPHOCYTES1. <i>Transplantation</i> , 1999, 67, 1418-1425.	1.0	51
141	Diuretics and β -blockers: Is there a risk for dyslipidemia?. <i>American Heart Journal</i> , 2000, 139, 174-184.	2.7	50
142	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	2.8	50
143	Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 919-925.	0.7	49
144	Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2612-2619.	4.5	48

#	ARTICLE	IF	CITATIONS
145	Antibody-Mediated Allograft Rejection. <i>Transplantation</i> , 2013, 95, 128-136.	1.0	48
146	Anemia After Kidney Transplantation; Its Prevalence, Risk Factors, and Independent Association With Graft and Patient Survival. <i>Transplantation</i> , 2012, 93, 923-928.	1.0	47
147	Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. <i>American Journal of Hypertension</i> , 2002, 15, 550-556.	2.0	46
148	Time to Achieve Blood-Pressure Goal: Influence of Dose of Valsartan Monotherapy and Valsartan and Hydrochlorothiazide Combination Therapy. <i>American Journal of Hypertension</i> , 2007, 20, 807-815.	2.0	46
149	A Study of Renal Outcomes in African American Living Kidney Donors. <i>Transplantation</i> , 2009, 88, 1371-1376.	1.0	46
150	Inadequacy of cardiovascular risk factor management in chronic kidney transplantation – evidence from the FAVORIT study. <i>Clinical Transplantation</i> , 2012, 26, E438-46.	1.6	46
151	Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29013-29024.	7.1	46
152	Long-term effects of patiomer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. <i>ESC Heart Failure</i> , 2018, 5, 592-602.	3.1	45
153	CORRELATION OF IN VITRO CD4+ T HELPER CELL FUNCTION WITH CLINICAL GRAFT STATUS IN IMMUNOSUPPRESSED KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1991, 52, 284-290.	1.0	44
154	First-Line Therapy Option with Low-Dose Bisoprolol Fumarate and Low-Dose Hydrochlorothiazide in Patients with Stage I and Stage II Systemic Hypertension. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 182-188.	2.0	44
155	Effect of Patiomer on Urinary Ion Excretion in Healthy Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1769-1776.	4.5	44
156	Therapeutic challenges in the obese diabetic patient with hypertension. <i>American Journal of Medicine</i> , 1996, 101, 33S-46S.	1.5	43
157	Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. <i>Translational Research</i> , 2018, 195, 25-47.	5.0	43
158	Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. <i>American Journal of Kidney Diseases</i> , 2019, 73, 827-836.	1.9	43
159	Pancreas Transplantation for Diabetes Mellitus. <i>American Journal of Kidney Diseases</i> , 1996, 27, 444-450.	1.9	42
160	Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. <i>American Journal of Hypertension</i> , 1998, 11, 914-920.	2.0	42
161	Cigarette Smoking, Kidney Function, and Mortality After Live Donor Kidney Transplant. <i>American Journal of Kidney Diseases</i> , 2010, 55, 907-915.	1.9	42
162	Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. <i>Journal of Hypertension</i> , 2009, 27, 886-893.	0.5	41

#	ARTICLE	IF	CITATIONS
163	Histological Grading of Chronic Pancreas Allograft Rejection/Graft Sclerosis. American Journal of Transplantation, 2003, 3, 599-605.	4.7	40
164	Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. Transplantation, 2003, 75, 1186-1190.	1.0	40
165	The metabolic syndrome: a call to action. Coronary Artery Disease, 2006, 17, 77-80.	0.7	39
166	Acute Kidney Injury following Cardiac Surgery: Role of Perioperative Blood Pressure Control. American Journal of Nephrology, 2011, 33, 438-452.	3.1	39
167	Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 306-313.	2.0	39
168	Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1493-1499.	4.5	39
169	MYCOPHENOLATE MOFETIL REDUCES THE RISK OF ACUTE REJECTION LESS IN AFRICAN-AMERICAN THAN IN CAUCASIAN KIDNEY RECIPIENTS ¹ . Transplantation, 1998, 65, 242-248.	1.0	39
170	RADIX Tripterygium Wilfordiiâ€”A CHINESE HERBAL MEDICINE WITH POTENT IMMUNOSUPPRESSIVE PROPERTIES. Transplantation, 1990, 50, 82-85.	1.0	38
171	Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: Blood pressure control and immunosuppression. American Journal of Medicine, 1991, 90, S32-S36.	1.5	38
172	Gender considerations in hypertension pathophysiology and treatment. American Journal of Medicine, 1996, 101, 10S-21S.	1.5	38
173	Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: A pilot case-control study. American Journal of Kidney Diseases, 2002, 39, 1096-1101.	1.9	38
174	Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. American Journal of Medicine, 2018, 131, 555-564.e3.	1.5	38
175	Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. American Heart Journal, 2020, 223, 3-11.	2.7	38
176	Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. American Journal of Nephrology, 2021, 52, 450-466.	3.1	38
177	Coxibsâ€”Beyond the GI Tract. Journal of Pain and Symptom Management, 2003, 25, 41-49.	1.2	37
178	The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clinical Transplantation, 2009, 23, 930-937.	1.6	37
179	Hemodynamic Correlates of Proteinuria in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2403-2410.	4.5	37
180	Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients. Transplantation, 2017, 101, 166-181.	1.0	37

#	ARTICLE	IF	CITATIONS
181	INCIDENCE OF CYTOMEGALOVIRUS DISEASE IN CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTS BASED ON DONOR/RECIPIENT PRETRANSPLANT IMMUNITY. <i>Transplantation</i> , 1987, 43, 187-192.	1.0	36
182	Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study. <i>American Journal of Nephrology</i> , 2017, 46, 323-332.	3.1	36
183	Salt and Blood Pressure Responses to Calcium Antagonism in Hypertensive Patients. <i>Hypertension</i> , 1997, 30, 422-427.	2.7	36
184	A Noninferiority Comparison of Valsartan/Hydrochlorothiazide Combination Versus Amlodipine in Black Hypertensives. <i>Hypertension</i> , 2005, 46, 508-513.	2.7	35
185	Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 184-193.	1.9	35
186	Diltiazem: Ten Years of Clinical Experience in the Treatment of Hypertension. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 220-232.	2.0	34
187	Reasons for discharges against medical advice: a qualitative study. <i>BMJ Quality and Safety</i> , 2010, 19, 420-424.	3.7	34
188	Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2019, 73, 785-793.	2.7	34
189	A prospective controlled study of metabolic and physiologic effects of kidney donation suggests that donors retain stable kidney function over the first nine years. <i>Kidney International</i> , 2020, 98, 168-175.	5.2	34
190	Pharmacologic management of systemic hypertension in blacks. <i>American Journal of Cardiology</i> , 1988, 61, H46-H52.	1.6	33
191	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. <i>American Journal of Medicine</i> , 2018, 131, 165-172.	1.5	33
192	Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2609-2621.	6.1	33
193	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238.	7.1	32
194	Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. <i>Current Opinion in Nephrology and Hypertension</i> , 2000, 9, 403-411.	2.0	31
195	Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. <i>Transplantation</i> , 2004, 77, 422-425.	1.0	31
196	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , 2012, 81, 568-576.	5.2	31
197	Effectiveness of informational decision aids and a live donor financial assistance program on pursuit of live kidney transplants in African American hemodialysis patients. <i>BMC Nephrology</i> , 2018, 19, 107.	1.8	31
198	ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?. <i>Journal of Clinical Hypertension</i> , 2002, 4, 420-440.	2.0	30

#	ARTICLE	IF	CITATIONS
199	The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 766-785.	4.5	30
200	A Pilot Study to Evaluate Renal Hemodynamics in Cirrhosis by Simultaneous Glomerular Filtration Rate, Renal Plasma Flow, Renal Resistive Indices and Biomarkers Measurements. <i>American Journal of Nephrology</i> , 2014, 39, 543-552.	3.1	30
201	Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. <i>American Journal of Kidney Diseases</i> , 2019, 73, 51-61.	1.9	30
202	Epidemiology and Pathophysiology of Glomerular C4d Staining in Native Kidney Biopsies. <i>Kidney International Reports</i> , 2019, 4, 1555-1567.	0.8	30
203	Impact of age, race, and obesity on hypertensive mechanisms and therapy. <i>American Journal of Medicine</i> , 1991, 90, S3-S14.	1.5	29
204	A dose-response trial of once-daily diltiazem. <i>American Heart Journal</i> , 1992, 123, 1022-1026.	2.7	29
205	Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. <i>American Journal of Hypertension</i> , 2000, 13, 1180-1188.	2.0	29
206	Are the oxygen costs of kidney function highly regulated?. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 67-71.	2.0	29
207	Hypertensive cardiovascular disease in African Americans. <i>Current Hypertension Reports</i> , 1999, 1, 521-528.	3.5	28
208	Albuminuria predicting outcome in diabetes: Incidence of microalbuminuria in Asia-Pacific Rim. <i>Kidney International</i> , 2004, 66, S38-S39.	5.2	28
209	mTOR inhibition: the learning curve in kidney transplantation. <i>Transplant International</i> , 2010, 23, 447-460.	1.6	28
210	Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1162-1166.	2.3	28
211	Human <i>GRK4^{142V}</i> Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition. <i>Hypertension</i> , 2016, 67, 325-334.	2.7	28
212	Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 434-446.	2.0	28
213	SAFE PANCREAS TRANSPLANTATION IN PATIENTS WITH CORONARY ARTERY DISEASE1. <i>Transplantation</i> , 1997, 63, 1294-1299.	1.0	28
214	INCIDENCE AND MORBIDITY OF CYTOMEGALOVIRUS DISEASE ASSOCIATED WITH A SERONEGATIVE RECIPIENT RECEIVING SEROPOSITIVE DONOR-SPECIFIC TRANSFUSION AND LIVING-RELATED DONOR TRANSPLANTATION. <i>Transplantation</i> , 1988, 45, 111-115.	1.0	27
215	Exercise-Induced Hypertension, Endothelial Dysfunction, and Coronary Artery Disease in a Marathon Runner. <i>American Journal of Cardiology</i> , 2007, 99, 743-744.	1.6	27
216	β-Blockers in the Treatment of Hypertension: Are There Clinically Relevant Differences?. <i>Postgraduate Medicine</i> , 2009, 121, 90-98.	2.0	27

#	ARTICLE	IF	CITATIONS
217	Current Concepts in the Diagnosis and Classification of Renal Dysfunction in Cirrhosis. <i>American Journal of Nephrology</i> , 2013, 38, 345-354.	3.1	27
218	HISTOLOGIC FINDINGS IN ISLETS OF WHOLE PANCREAS ALLOGRAFTS. <i>Transplantation</i> , 1996, 62, 1770-1772.	1.0	27
219	Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 1491-1495.	3.4	26
220	Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS). <i>American Heart Journal</i> , 2006, 152, 867-875.	2.7	26
221	Clinical perspectives on the rationale for potassium supplementation. <i>Postgraduate Medicine</i> , 2015, 127, 539-548.	2.0	26
222	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. <i>Journal of Clinical Hypertension</i> , 2016, 18, 299-307.	2.0	26
223	Habitual sleep and kidney function in chronic kidney disease: the Chronic Renal Insufficiency Cohort study. <i>Journal of Sleep Research</i> , 2018, 27, 283-291.	3.2	26
224	The rationale for combination versus single-entity therapy in hypertension. <i>American Journal of Hypertension</i> , 1998, 11, 163S-169S.	2.0	25
225	Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs. <i>Cardiovascular Therapeutics</i> , 2012, 30, 342-350.	2.5	25
226	Editorial Perspective. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial. <i>American Journal of Nephrology</i> , 2010, 31, 469-470.	3.1	24
227	Hypertension. <i>Annals of Internal Medicine</i> , 2014, 161, ITC1.	3.9	24
228	The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. <i>Postgraduate Medicine</i> , 2016, 128, 290-298.	2.0	24
229	Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 624-632.e2.	4.4	24
230	Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 585-595.	4.5	24
231	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. <i>American Journal of Kidney Diseases</i> , 2019, 73, 437-458.	1.9	24
232	Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure. <i>American Journal of Cardiology</i> , 1990, 66, D14-D21.	1.6	23
233	Blood pressure management in the kidney transplant recipient. <i>Advances in Chronic Kidney Disease</i> , 2004, 11, 172-183.	1.4	23
234	Effects of High- and Low-Sodium Diets on Ambulatory Blood Pressure in Patients With Hypertension Receiving Aliskiren. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 356-363.	2.0	23

#	ARTICLE	IF	CITATIONS
235	Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 665-675.	2.3	23
236	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	2.3	23
237	Renal adaptation to the failing heart. <i>Postgraduate Medicine</i> , 1994, 95, 153-156.	2.0	22
238	The tissue renin-angiotensin-aldosterone system in diabetes mellitus. <i>Current Hypertension Reports</i> , 2004, 6, 98-105.	3.5	22
239	The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. <i>American Journal of Hypertension</i> , 2005, 18, 100-105.	2.0	22
240	Evaluation of the Dose Response With Valsartan and Valsartan/Hydrochlorothiazide in Patients With Essential Hypertension. <i>Journal of Clinical Hypertension</i> , 2007, 9, 103-112.	2.0	22
241	Risk-Based Classification of Hypertension and the Role of Combination Therapy. <i>Journal of Clinical Hypertension</i> , 2008, 10, 4-12.	2.0	22
242	Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 614-621.	1.6	22
243	Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. <i>American Journal of Kidney Diseases</i> , 2017, 70, 762-769.	1.9	22
244	ADDITIVE INHIBITION OF AFFERENT AND EFFERENT IMMUNOLOGICAL RESPONSES OF HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS BY VERAPAMIL AND CYCLOSPORINE. <i>Transplantation</i> , 1991, 51, 851-857.	1.0	21
245	Does dietary salt increase the risk for progression of kidney disease?. <i>Current Hypertension Reports</i> , 2005, 7, 385-391.	3.5	21
246	Usefulness of ARBs and ACE Inhibitors in the Prevention of Vascular Dementia in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2007, 16, 175-182.	0.6	21
247	Combination Therapy With Renin-Angiotensin-Aldosterone Receptor Blockers for Hypertension: How Far Have We Come?. <i>Journal of Clinical Hypertension</i> , 2008, 10, 146-152.	2.0	21
248	Hypertension and the Kidney. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 2045-2050.	4.5	21
249	Does Blockade of the Renin-Angiotensin-Aldosterone System Slow Progression of All Forms of Kidney Disease?. <i>Current Hypertension Reports</i> , 2010, 12, 369-377.	3.5	21
250	Determinants of Blood Pressure Response to Low-Salt Intake in a Healthy Adult Population. <i>Journal of Clinical Hypertension</i> , 2011, 13, 795-800.	2.0	21
251	Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. <i>Current Medical Research and Opinion</i> , 2017, 33, 1891-1900.	1.9	21
252	Effectiveness of patiomer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. <i>Journal of Hypertension</i> , 2017, 35, S57-S63.	0.5	21

#	ARTICLE	IF	CITATIONS
253	KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2022, 79, 311-327.	1.9	21
254	Salt intake and hypertensive renal injury in African-Americans a therapeutic perspective. <i>American Journal of Hypertension</i> , 1995, 8, 635-644.	2.0	20
255	Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. <i>Clinical Transplantation</i> , 2007, 21, 491-497.	1.6	20
256	Genetic influences on blood pressure response to the cold pressor test: results from the Heredity and Phenotype Intervention Heart Study. <i>Journal of Hypertension</i> , 2008, 26, 729-736.	0.5	20
257	Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. <i>Kidney International</i> , 2016, 90, 861-868.	5.2	20
258	Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term Follow-up. <i>Transplantation</i> , 2016, 100, 407-415.	1.0	20
259	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 155-164.	1.8	20
260	Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. <i>American Journal of Cardiology</i> , 1987, 60, 36-41.	1.6	19
261	EVIDENCE THAT THE ANTIPROLIFERATIVE EFFECT OF VERAPAMIL ON AFFERENT AND EFFERENT IMMUNE RESPONSES IS INDEPENDENT OF CALCIUM CHANNEL INHIBITION. <i>Transplantation</i> , 1992, 54, 681-685.	1.0	19
262	Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, S10-S19.	0.9	19
263	Minimization of Indomethacin-Induced Reduction in Renal Function by Misoprostol. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 729-735.	2.0	18
264	Providing End-Organ Protection With Renin-Angiotensin System Inhibition: The Evidence So Far. <i>Journal of Clinical Hypertension</i> , 2006, 8, 99-107.	2.0	18
265	Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. <i>Future Cardiology</i> , 2007, 3, 519-524.	1.2	18
266	Safety and Feasibility of Achieving Lower Systolic Blood Pressure Goals in Persons With Type 2 Diabetes: The SANDS Trial. <i>Journal of Clinical Hypertension</i> , 2009, 11, 540-548.	2.0	18
267	Minimizing the Risk of Chronic Allograft Nephropathy. <i>Transplantation</i> , 2009, 87, S14-S18.	1.0	18
268	Thiazide and Thiazide-like Diuretics: An Opportunity to Reduce Blood Pressure in Patients with Advanced Kidney Disease. <i>Current Hypertension Reports</i> , 2012, 14, 416-420.	3.5	18
269	Influence of Creatinine versus Glomerular Filtration Rate on Non-Steroidal Anti-Inflammatory Drug Prescriptions in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2012, 36, 19-26.	3.1	18
270	Defining, Treating, and Understanding Chronic Kidney Disease—A Complex Disorder. <i>Journal of Clinical Hypertension</i> , 2015, 17, 514-527.	2.0	18

#	ARTICLE	IF	CITATIONS
271	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. <i>Canadian Journal of Diabetes</i> , 2016, 40, 247-257.	0.8	18
272	Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1409-1417.	4.5	18
273	Donor-derived Cell-free DNA in Infections in Kidney Transplant Recipients: Case Series. <i>Transplantation Direct</i> , 2020, 6, e568.	1.6	18
274	Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 139-147.	0.7	18
275	Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1396-1402.	2.9	18
276	Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. <i>European Journal of Heart Failure</i> , 2009, 11, 542-550.	7.1	17
277	A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting: Figure 1. <i>BMJ Open</i> , 2012, 2, e000902.	1.9	17
278	Prevalence, Severity, and Impact of Renal Dysfunction in Acute Liver Failure on the US Liver Transplant Waiting List. <i>Digestive Diseases and Sciences</i> , 2016, 61, 309-316.	2.3	17
279	REEVALUATION OF T CELL SUBSET MONITORING IN CYCLOSPORINE-TREATED RENAL ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1985, 40, 620-623.	1.0	16
280	The Future of Clinical Trials in Chronic Renal Disease: Outcome of an NIH/FDA/Physician Specialist Conference. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 815-825.	2.0	16
281	The Efficacy and Safety of Initial Use of Irbesartan/Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Patients With and Without High Cardiovascular Risk. <i>Journal of Clinical Hypertension</i> , 2007, 9, 23-30.	2.0	16
282	Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. <i>Journal of Hypertension</i> , 2010, 28, 186-193.	0.5	16
283	A Randomized, Double-Blind, Forced-Titration Study to Compare Olmesartan Medoxomil versus Losartan Potassium in Patients with Stage 1 and 2 Hypertension. <i>Postgraduate Medicine</i> , 2011, 123, 80-87.	2.0	16
284	Treated hypertension and the white coat phenomenon: Office readings are inadequate measures of efficacy. <i>Journal of the American Society of Hypertension</i> , 2013, 7, 236-243.	2.3	16
285	Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications. <i>Kidney International</i> , 2017, 91, 529-531.	5.2	16
286	Comparison of Dual RAAS Blockade and Higher-Dose RAAS Inhibition on Nephropathy Progression. <i>Postgraduate Medicine</i> , 2008, 120, 33-42.	2.0	15
287	The balance of angiotensin II and nitric oxide in kidney diseases. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 51-56.	2.0	15
288	Have we fallen off target with concerns surrounding dual RAAS blockade?. <i>Kidney International</i> , 2010, 78, 539-545.	5.2	15

#	ARTICLE	IF	CITATIONS
289	Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success?. <i>Kidney International</i> , 2011, 80, 235-237.	5.2	15
290	Management of hypertension in the transplant patient. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 425-432.	2.3	15
291	Specific Management of Anemia and Hypertension in Renal Transplant Recipients: Influence of Renin-Angiotensin System Blockade. <i>American Journal of Nephrology</i> , 2014, 39, 1-7.	3.1	15
292	Late intervention with the small molecule BB3 mitigates postischemic kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F352-F361.	2.7	15
293	Determinants of the renal response to ACE inhibition in patients with congestive heart failure. <i>American Heart Journal</i> , 1992, 124, 131-136.	2.7	14
294	Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. <i>Clinical Cardiology</i> , 1997, 20, 562-568.	1.8	14
295	Impact of Salt Intake on Blood Pressure and Proteinuria in Diabetes: Importance of the Renin-Angiotensin System. <i>Mineral and Electrolyte Metabolism</i> , 1998, 24, 438-445.	1.1	14
296	Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. <i>Transplantation</i> , 2017, 101, 157-165.	1.0	14
297	Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials. <i>JAMA Cardiology</i> , 2022, 7, 549.	6.1	14
298	RENAL ALLOGRAFT BIOPSY AND CONVERSION OF CYCLOSPORINE TO AZATHIOPRINE. <i>Transplantation</i> , 1989, 47, 223-228.	1.0	13
299	The Renoprotective Effects of RAS Inhibition: Focus on Prevention and Treatment of Chronic Kidney Disease. <i>Postgraduate Medicine</i> , 2009, 121, 96-103.	2.0	13
300	Treatment-Resistant Hypertension in the Transplant Recipient. <i>Seminars in Nephrology</i> , 2014, 34, 560-570.	1.6	13
301	Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e011013.	3.7	13
302	Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2019, 25, 436-447.	1.7	13
303	Association of 24-Hour Ambulatory Blood Pressure Patterns with Cognitive Function and Physical Functioning in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 455-464.	4.5	13
304	Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort. <i>Hypertension</i> , 2021, 77, 72-81.	2.7	13
305	Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program. <i>Drugs - Real World Outcomes</i> , 2021, 8, 315-323.	1.6	13
306	Real-World Diagnosis and Treatment of Diabetic Kidney Disease. <i>Advances in Therapy</i> , 2021, 38, 4425-4441.	2.9	13

#	ARTICLE	IF	CITATIONS
307	Current perspective on the cardiovascular effects of coxibs.. Cleveland Clinic Journal of Medicine, 2002, 69, S147-S147.	1.3	13
308	Hypertensive nephropathy: Is a more physiologic approach to blood pressure control an important concern for the preservation of renal function?. American Journal of Medicine, 1992, 93, S27-S37.	1.5	12
309	Progressive renal and cardiovascular disease: Optimal treatment strategies. Kidney International, 2002, 62, 1482-1492.	5.2	12
310	Hypervolemia and Blood Pressure. Hypertension, 2010, 56, 341-343.	2.7	12
311	Urinary Sodium Is a Potent Correlate of Proteinuria: Lessons from the Chronic Renal Insufficiency Cohort Study. American Journal of Nephrology, 2012, 36, 397-404.	3.1	12
312	Eosinophilia as an early indicator of pancreatic allograft rejection. Clinical Transplantation, 2012, 26, 238-241.	1.6	12
313	Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation. Kidney360, 2021, 2, 1998-2009.	2.1	12
314	Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. Transplantation, 2021, 105, 443-450.	1.0	12
315	Telmisartan in incipient and overt diabetic renal disease. Journal of Nephrology, 2011, 24, 263-273.	2.0	12
316	Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function. Clinical Nephrology, 2018, 89, 314-329.	0.7	12
317	Physiologic and hemodynamic considerations in blood pressure control while maintaining organ perfusion. American Journal of Cardiology, 1988, 61, H60-H66.	1.6	11
318	Calcium channel blockers inhibit cellular uptake of thymidine, uridine and leucine: the incorporation of these molecules into DNA, RNA and protein in the presence of calcium channel blockers is not a valid measure of lymphocyte activation. Immunopharmacology, 1993, 25, 75-82.	2.0	11
319	Blood pressure and cardiovascular risks: implications of the presence or absence of a nocturnal dip in blood pressure. Current Opinion in Nephrology and Hypertension, 2003, 12, 57-60.	2.0	11
320	Pharmacological strategies for kidney function preservation: are there differences by ethnicity?. Advances in Chronic Kidney Disease, 2004, 11, 24-40.	2.1	11
321	Readmissions After Unauthorized Discharges in the Cardiovascular Setting. Medical Care, 2011, 49, 215-224.	2.4	11
322	The Role of Angiotensin Receptor Blockers in Diabetic Nephropathy. Postgraduate Medicine, 2011, 123, 109-121.	2.0	11
323	The Role of ARBs Alone or with HCTZ in the Treatment of Hypertension and Prevention of Cardiovascular and Renal Complications. Postgraduate Medicine, 2012, 124, 40-52.	2.0	11
324	Current and future treatment options for managing hyperkalemia. Kidney International Supplements, 2016, 6, 29-34.	14.2	11

#	ARTICLE	IF	CITATIONS
325	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non- ν -Vitamin K Antagonist Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1503-1519.	3.0	11
326	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2019, 74, 771-781.	1.9	11
327	Hyperkalemia management in the emergency department: An expert panel consensus. <i>Journal of the American College of Emergency Physicians Open</i> , 2021, 2, e12572.	0.7	11
328	Optimal strategies for modeling the reciprocal of creatinine versus time in renal transplant recipients and patients with native chronic renal disease. <i>American Journal of Kidney Diseases</i> , 2002, 39, 753-761.	1.9	10
329	Dietary Salt, Blood Pressure, and Microalbuminuria. <i>Journal of Clinical Hypertension</i> , 2004, 6, 23-26.	2.0	10
330	Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: A post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. <i>Clinical Therapeutics</i> , 2008, 30, 2354-2365.	2.5	10
331	Prescribing Trends and Drug Budget Impact of the ARBs in the UK. <i>Value in Health</i> , 2009, 12, 302-308.	0.3	10
332	Anemia and Incident End-Stage Kidney Disease. <i>Kidney360</i> , 2020, 1, 623-630.	2.1	10
333	Hypertension in Diabetic Patients: An Update of Interventional Studies to Preserve Renal Function. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 73-80.	2.0	9
334	COX-2 Inhibitors And Cardiovascular Risk. <i>Sub-Cellular Biochemistry</i> , 2007, 42, 159-174.	2.4	9
335	Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 416-421.	2.0	9
336	Renin Angiotensin System Inhibition in the Older Person: A Review. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 245-257.	2.6	9
337	Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1429-1434.	3.4	9
338	Achieving lipid targets in adults with type 2 diabetes: The \hat{A} Stop Atherosclerosis in Native Diabetics Study. <i>Journal of Clinical Lipidology</i> , 2010, 4, 435-443.	1.5	9
339	Role of dietary therapies in the prevention and treatment of hypertension. <i>Nature Reviews Nephrology</i> , 2012, 8, 413-422.	9.6	9
340	The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient. <i>Current Cardiology Reports</i> , 2015, 17, 95.	2.9	9
341	Focus on Hyperkalemia Management: Expert Consensus and Economic Impacts. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, S2-S20.	0.9	9
342	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , 2020, 51, 276-288.	3.1	9

#	ARTICLE	IF	CITATIONS
343	Recognizing the link between chronic kidney disease and cardiovascular disease. American Journal of Managed Care, 2011, 17 Suppl 15, S396-402.	1.1	9
344	Effect of Dietary Sodium on Insulin Sensitivity in Older, Obese, Sedentary Hypertensives. American Journal of Hypertension, 1997, 10, 964-970.	2.0	8
345	Efficacy of Low-Dose Combination of Bisoprolol/Hydrochlorothiazide Compared With Amlodipine and Enalapril in Men and Women With Essential Hypertension. American Journal of Cardiology, 1998, 81, 1363-1365.	1.6	8
346	The β Blockers: Are They as Protective in Hypertension as in other Cardiovascular Conditions?. Journal of Clinical Hypertension, 2001, 3, 236-243.	2.0	8
347	Calcium Channel Blockers: Their Pharmacologic and Therapeutic Role in Hypertension. American Journal of Cardiovascular Drugs, 2007, 7, 5??15.	2.2	8
348	A single center comparison of long-term outcomes of renal allografts procured laparoscopically versus historic controls procured by the open approach. Transplant International, 2008, 21, 908-914.	1.6	8
349	Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (<scp>MAGMA</scp>) Trial. Clinical Cardiology, 2017, 40, 633-640.	1.8	8
350	Blood Pressure and Living Kidney Donors: A Clinical Perspective. Transplantation Direct, 2019, 5, e488.	1.6	8
351	Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. Future Science OA, 2020, 6, FSO441.	1.9	8
352	Reserpine: A New Consideration of an Old Drug for Refractory Hypertension. American Journal of Hypertension, 2020, 33, 708-710.	2.0	8
353	Causes of Renal Allograft Injury in Recipients With Normal Donor-derived Cell-free DNA. Transplantation Direct, 2021, 7, e679.	1.6	8
354	LATE PANCREAS ALLOGRAFT REJECTION. Transplantation, 1996, 62, 539-543.	1.0	8
355	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	2.2	8
356	Essential Hypertension in Blacks: Is It a Metabolic Disorder?. American Journal of Kidney Diseases, 1993, 21, 58-67.	1.9	7
357	Reduction in Microalbuminuria. Hypertension, 2005, 45, 181-182.	2.7	7
358	Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: The Stop Atherosclerosis in Native Diabetics Study (SANDS). Journal of Clinical Lipidology, 2010, 4, 165-172.	1.5	7
359	Body Mass Index-Mortality Paradox in Hemodialysis Patients. Hypertension, 2011, 58, 989-990.	2.7	7
360	Efficacy of Amlodipine/Olmesartan Medoxomil \pm Hydrochlorothiazide in Patients Aged \geq 65 or $<$ 65 Years With Uncontrolled Hypertension on Prior Monotherapy. Postgraduate Medicine, 2013, 125, 124-134.	2.0	7

#	ARTICLE	IF	CITATIONS
361	Usability of Mobile Technology to Screen for Drug-Drug Interactions in Kidney Transplant Patients. American Journal of Nephrology, 2014, 40, 97-104.	3.1	7
362	A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. American Journal of Nephrology, 2017, 46, 364-370.	3.1	7
363	Hyperkalemia in the Hypertensive Patient. Current Cardiology Reports, 2018, 20, 12.	2.9	7
364	Kidney transplant candidacy evaluation and waitlisting practices in the United States and their association with access to transplantation. American Journal of Transplantation, 2022, 22, 1624-1636.	4.7	7
365	Is Activated Vitamin D Supplementation Renoprotective?. Hypertension, 2008, 52, 211-212.	2.7	6
366	Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. Kidney International, 2011, 80, 1016-1017.	5.2	6
367	Debate from the 2012 ASH Annual Scientific Sessions: should blood pressure be reduced in hemodialysis patients? con position. Journal of the American Society of Hypertension, 2012, 6, 443-447.	2.3	6
368	Blood pressure response with fixed-dose combination therapy. Journal of Hypertension, 2013, 31, 1692-1701.	0.5	6
369	CCR2 inhibition: a panacea for diabetic kidney disease?. Lancet Diabetes and Endocrinology, the, 2015, 3, 666-667.	11.4	6
370	New Agents for Hyperkalemia. New England Journal of Medicine, 2015, 372, 1569-1572.	27.0	6
371	Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. Journal of Diabetes and Its Complications, 2021, 35, 108029.	2.3	6
372	Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD. Kidney360, 2022, 3, 859-871.	2.1	6
373	Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction. Journal of Clinical Hypertension, 2004, 6, 315-325.	2.0	5
374	Renal Function and Cardiovascular Response to Mental Stress. American Journal of Nephrology, 2008, 28, 304-310.	3.1	5
375	Hypertension and kidney disease. Journal of the American Society of Hypertension, 2014, 8, 855-857.	2.3	5
376	Salt, hypertension, and proteinuria in diabetic nephropathy. Lancet Diabetes and Endocrinology, the, 2014, 2, 351-352.	11.4	5
377	Safety Events in Kidney Transplant Recipients. Transplantation, 2015, 99, 1003-1008.	1.0	5
378	Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. International Journal of Nephrology and Renovascular Disease, 2017, Volume 10, 233-242.	1.8	5

#	ARTICLE	IF	CITATIONS
379	Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017, Volume 11, 1-7.	1.8	5
380	Effect of Levothyroxine on Kidney Function in Chronic Kidney Disease with Subclinical Hypothyroidism in US Veterans: A Retrospective Observational Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 1185-1201.	2.9	5
381	Prediction of Incident Heart Failure in CKD: The CRIC Study. <i>Kidney International Reports</i> , 2022, 7, 708-719.	0.8	5
382	The Effects of Candesartan Cilexetil in Isolated Systolic Hypertension: A Clinical Experience Trial. <i>Journal of Clinical Hypertension</i> , 2000, 2, 181-186.	2.0	5
383	Evaluation of the Clinical Pharmacology of Nilvadipine in Patients with Mild to Moderate Essential Hypertension. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 425-437.	2.0	4
384	Supplementation of Immunosuppressive Regimens with Calcium Channel Blockers. <i>BioDrugs</i> , 1994, 2, 458-467.	0.7	4
385	VALUE OF IN VITRO CD4+ T HELPER CELL FUNCTION TEST FOR PREDICTING LONG-TERM LOSS OF HUMAN RENAL ALLOGRAFTS. <i>Transplantation</i> , 1994, 57, 480-482.	1.0	4
386	Renin inhibition and microalbuminuria development: meaningful predictor of kidney disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2010, 19, 437-443.	2.0	4
387	Optimal Blood Pressure for a Patient with Type 2 Diabetes Mellitus: Insight from the ACCORD Study. <i>Current Hypertension Reports</i> , 2010, 12, 313-315.	3.5	4
388	Relative Plasma Volume Monitoring and Blood Pressure Control. <i>Hypertension</i> , 2010, 55, 226-227.	2.7	4
389	Improving the Estimating Equation for GFR – A Clinical Perspective. <i>New England Journal of Medicine</i> , 2012, 367, 75-76.	27.0	4
390	Vascular stiffness as a surrogate measure of mortality in patients with chronic kidney disease. <i>Journal of Hypertension</i> , 2014, 32, 744-745.	0.5	4
391	Patiromer Reduces Serum K+ in Hyperkalemic Patients with HF and CKD on RAAS Inhibitors: Results from OPAL-HK and AMETHYST-DN. <i>Journal of Cardiac Failure</i> , 2015, 21, S107-S108.	1.7	4
392	Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies. <i>Journal of Diabetes</i> , 2019, 11, 619-622.	1.8	4
393	Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14326.	1.6	4
394	Time-specific associations of wearable sensor-based cardiovascular and behavioral readouts with disease phenotypes in the outpatient setting of the Chronic Renal Insufficiency Cohort. <i>Digital Health</i> , 2022, 8, 205520762211079.	1.8	4
395	Risk for renal injury in diabetic hypertensive patients. <i>Postgraduate Medicine</i> , 1992, 91, 77-84.	2.0	3
396	Preventing renal disease progression: Is it the drug or the blood pressure reduction, or both?. <i>Current Hypertension Reports</i> , 2000, 2, 497-499.	3.5	3

#	ARTICLE	IF	CITATIONS
397	The Inevitability of Renal Function Loss in Patients with Hypercreatinemia. American Journal of Nephrology, 2001, 21, 386-389.	3.1	3
398	Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients?. Transplantation Reviews, 2003, 17, 20-30.	2.9	3
399	Clinical trials report. Current Hypertension Reports, 2004, 6, 365-368.	3.5	3
400	Newer Combination Therapies in the Management of Hypertension: An Update. Journal of Clinical Hypertension, 2008, 10, 398-405.	2.0	3
401	Optimal Dietary Strategies for Reducing Incident Hypertension. Hypertension, 2009, 54, 698-699.	2.7	3
402	What Is Left Ventricular Hypertrophy and Is There a Reason to Regress Left Ventricular Hypertrophy?. Journal of Clinical Hypertension, 2009, 11, 407-410.	2.0	3
403	Refractory Hypertension. Hypertension, 2014, 63, 447-448.	2.7	3
404	Is There an Optimal Strategy for Pretransplant Cardiovascular Screening?. Transplantation, 2015, 99, 656-657.	1.0	3
405	Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. Postgraduate Medicine, 2019, 131, 367-375.	2.0	3
406	Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm. Kidney360, 2020, 1, 1146-1154.	2.1	3
407	The Importance of Bringing Transplantation Tolerance to the Clinic. Transplantation, 2021, 105, 935-940.	1.0	3
408	The Use of Thiazides in Chronic Kidney Disease. Current Hypertension Reviews, 2015, 10, 81-85.	0.9	3
409	Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes. Diabetes Therapy, 2021, 12, 3167-3186.	2.5	3
410	Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression. American Journal of Nephrology, 2022, 53, 513-515.	3.1	3
411	ENZYME-LINKED IMMUNOSORBENT ASSAY FOR SERUM RENAL TUBULAR ANTIGEN IN KIDNEY TRANSPLANT PATIENTS. Transplantation, 1985, 40, 642-647.	1.0	2
412	The role of angiotensin II and TGF-beta on the progression of chronic allograft nephropathy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S188-S190.	1.7	2
413	Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Current Hypertension Reports, 2002, 4, 333-335.	3.5	2
414	Chronic kidney disease: Blood pressure, treatment goals, and cardiovascular outcomes. Current Hypertension Reports, 2003, 5, 405-407.	3.5	2

#	ARTICLE	IF	CITATIONS
415	Blood pressure salt sensitivity: a biomeasure of kidney disease susceptibility in diabetics?. Nephrology Dialysis Transplantation, 2005, 20, 2022-2024.	0.7	2
416	How Do You Define "Hypertension" in a Patient With Type 1 Diabetes?. Hypertension, 2007, 49, 13-14.	2.7	2
417	Gauging adequacy of cardiovascular disease treatment: importance of estimating glomerular filtration rate and time-varying albuminuria. Journal of the American Society of Hypertension, 2009, 3, 277-285.	2.3	2
418	Dietary Fructose and Elevated Levels of Blood Pressure. Journal of the American Society of Nephrology: JASN, 2010, 21, 1416-1418.	6.1	2
419	Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. Journal of Hypertension, 2011, 29, 2031-2037.	0.5	2
420	Lower Blood Pressure (BP) with Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM). Canadian Journal of Diabetes, 2013, 37, S3.	0.8	2
421	Nonsteroidal MRA added to RAS blockade reduces albuminuria. Nature Reviews Nephrology, 2015, 11, 691-692.	9.6	2
422	Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: Results from OPAL-HK. Heart and Lung: Journal of Acute and Critical Care, 2015, 44, 550.	1.6	2
423	Diabetic nephropathy after kidney transplantation in patients with pretransplantation type II diabetes: A retrospective case series study from a high-volume center in the United States. Clinical Transplantation, 2018, 32, e13425.	1.6	2
424	Therapeutic Potential of Newer Drugs for Treating Hyperkalemia. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 787-788.	4.5	2
425	An evidence-based appraisal of complementary and alternative medicine strategies for the management of hypertension. Journal of Hypertension, 2020, 38, 1412-1419.	0.5	2
426	Should Renin-Angiotensin System Blockade Be Avoided in Patients With Declining Kidney Function?. American Journal of Kidney Diseases, 2020, 76, 739-741.	1.9	2
427	A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. Journal of the American Society of Nephrology: JASN, 2021, 32, 469-478.	6.1	2
428	Renal Protection in Chronic Kidney Disease. , 2005, , 281-294.		2
429	RECIPIENT OUTCOME AFTER RECEIVING A LAPROSCOPICALLY HARVESTED KIDNEY FROM A LIVING DONOR. Transplantation, 2001, 72, 355-356.	1.0	2
430	Apparent Treatment-Resistant Hypertension Assessed by Office and Ambulatory Blood Pressure in Chronic Kidney Disease—A Report from the Chronic Renal Insufficiency Cohort Study. Kidney360, 2020, 1, 810-818.	2.1	2
431	Emergency Department/Urgent Care as Usual Source of Care and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort Study. Kidney Medicine, 2022, 4, 100424.	2.0	2
432	How Low Should We Treat Blood Pressure and Why?. Journal of Clinical Hypertension, 1999, 1, 199-208.	2.0	2

#	ARTICLE	IF	CITATIONS
433	Preliminary Observations of the Acute Effects of Selective Serum Thromboxane Inhibition and Angiotensin Converting Enzyme Inhibition on Blood Pressure and Renal Hemodynamics in Hypertensive Humans. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 1108-1116.	2.0	1
434	Risk for renal injury in diabetic hypertensive patients. <i>Postgraduate Medicine</i> , 1992, 91, 87-95.	2.0	1
435	The influence of dietary salt on the antiproteinuric effect of calcium channel blockers. <i>American Journal of Kidney Diseases</i> , 1997, 29, 800-803.	1.9	1
436	Optimizing target-organ protection in patients with diabetes mellitus: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?. <i>Current Hypertension Reports</i> , 2003, 5, 192-198.	3.5	1
437	Comparison of the effects of valsartan HCT versus amlodipine on 24-hour abpm blood pressure in african americans with mild to moderate hypertension: the aadvance trial. <i>American Journal of Hypertension</i> , 2004, 17, S112-S113.	2.0	1
438	The clinical utilization of albuminuria as a surrogate measure of cardiovascular disease burden and risk for events: are we there yet?. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 39-41.	2.0	1
439	Cyclosporine reduction causes decreasing of angiotensin II and transforming growth factor-beta expression in chronic allograft nephropathy. <i>Journal of Cardiothoracic-Renal Research</i> , 2006, 1, 81-88.	0.1	1
440	Clinical trials report. <i>Current Hypertension Reports</i> , 2006, 8, 393-394.	3.5	1
441	Assessing the Blood Pressure—Lowering Efficacy of Antihypertensive Medications: Which Blood Pressures Should We Use?. <i>Journal of Clinical Hypertension</i> , 2009, 11, 155-158.	2.0	1
442	The Death of John Paul Jones and Resurrection as “Father of the US Navy”. <i>American Journal of Nephrology</i> , 2010, 31, 90-94.	3.1	1
443	Endothelin-receptor antagonists for treating hypertension. <i>Nature Reviews Nephrology</i> , 2010, 6, 192-194.	9.6	1
444	Optimal Treatment Strategies for Patients With Hypertension and Diabetes. <i>Hypertension</i> , 2011, 58, 758-759.	2.7	1
445	Angiotensin II Blockade after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 167-168.	6.1	1
446	Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child—Turcotte—Pugh Class C Cirrhosis and Renal Dysfunction. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3491-3494.	2.3	1
447	The Tyranny of Generic Immunosuppressants. <i>American Journal of Nephrology</i> , 2016, 44, 204-205.	3.1	1
448	Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?. <i>European Journal of Heart Failure</i> , 2016, 18, 216-216.	7.1	1
449	Noteworthy observations in hypertension from 2015. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 1-2.	2.0	1
450	Serum Creatinine in Female Patients with Cirrhosis Unfairly Bias Liver Transplant Wait List Ranking: Implications for Elimination of Gender Disparities in Access to Orthotopic Liver Transplantation. <i>Gastroenterology</i> , 2017, 152, S1120.	1.3	1

#	ARTICLE	IF	CITATIONS
451	Robust Metabolomic Signature is Associated with Altered Renal Hemodynamics in Patients with Cirrhosis. <i>Gastroenterology</i> , 2017, 152, S1044.	1.3	1
452	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e349-e351.	1.5	1
453	Global Health Training Opportunities in North American Nephrology Fellowships. <i>Kidney International Reports</i> , 2019, 4, 904-907.	0.8	1
454	Hematologic and Infectious Complications of Chronic Kidney Disease. , 2020, , 477-502.		1
455	Response to letter regarding article "Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease": <i>American Heart Journal</i> , 2020, 223, 111-112.	2.7	1
456	LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE "EGFR DIP"™ IN EMPA-REG OUTCOME. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
457	Association Between APOL1 Genotype and Need for Kidney Replacement Therapy in Patients Without Diabetes: Does Age Matter?. <i>American Journal of Kidney Diseases</i> , 2020, 75, 294-296.	1.9	1
458	Patients'™ and family members'™ perspectives on arrhythmias and sudden death in dialysis: the HeartLink focus groups pilot study. <i>BMC Nephrology</i> , 2021, 22, 199.	1.8	1
459	Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the <sc>CANVAS</sc> Program and <sc>CREDESCENCE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 12-20.	4.4	1
460	Antihypertensive Drugs. , 2012, , 1824-1878.		1
461	Pharmacogenomics of G Protein-Coupled Receptor Signaling and Other Pathways in Essential Hypertension. <i>Methods in Pharmacology and Toxicology</i> , 2014, , 299-312.	0.2	1
462	The Role of Multiple Drug Therapy for Controlling Hypertension in African Americans. <i>Journal of Clinical Hypertension</i> , 2000, 2, 99-108.	2.0	1
463	Hypertension: Goal systolic and diastolic blood pressure. <i>Current Hypertension Reports</i> , 1999, 1, 411-413.	3.5	0
464	From hypertension to heart disease: interfering with progression Diabetes and hypertension: blood pressure control benefits and consequences.. <i>American Journal of Hypertension</i> , 1999, 12, 222.	2.0	0
465	Indicators and Treatment of Hypertensive Heart Disease. <i>Hospital Practice (1995)</i> , 1999, 34, 93-107.	1.0	0
466	Achieving low blood pressure for the kidney: is there really a problem? Wednesday, may 17, broadway ballroom north, 3:00 pm to 5:00 pm. new blood pressure goals: reality or fantasy-the importance of combination therapy. <i>American Journal of Hypertension</i> , 2000, 13, S329.	2.0	0
467	Implications from the Heart Outcomes Prevention Evaluation Study. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 61-63.	2.0	0
468	Hypertension in Patients with Type 2 Diabetes. <i>Hospital Practice (1995)</i> , 2001, 36, 41-54.	1.0	0

#	ARTICLE	IF	CITATIONS
469	Appropriate Use of Calcium Antagonists in Hypertension. <i>Hospital Practice</i> (1995), 2001, 36, 47-55.	1.0	0
470	Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, S217-S222.	1.7	0
471	Advances in the management of hypertension and diabetes: Why we need to integrate biology, evidence, and treatment strategies. <i>American Journal of Hypertension</i> , 2004, 17, S1-S1.	2.0	0
472	Healthy Diet and Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2004, 6, 381-382.	2.0	0
473	Direct renin inhibitors: Where will they fit in for antihypertensive treatment?. <i>Current Hypertension Reports</i> , 2007, 9, 389-391.	3.5	0
474	Are we "ONTARGET" yet with regard to optimal antihypertensive regimens?. <i>Current Hypertension Reports</i> , 2008, 10, 385-386.	3.5	0
475	The Obesity Paradox: Impact of Obesity on the Prevalence and Prognosis of Cardiovascular Diseases. <i>Postgraduate Medicine</i> , 2009, 121, 164-165.	2.0	0
476	52 Prevalence of CVD Risk Factors and their Treatment in Chronic, Stable Kidney Transplant Recipients in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. <i>American Journal of Kidney Diseases</i> , 2011, 57, B29.	1.9	0
477	Response to Letter Regarding Article, "Acute Kidney Injury and Cardiovascular Outcomes in Acute Severe Hypertension". <i>Circulation</i> , 2011, 123, .	1.6	0
478	The Author Replies:. <i>Kidney International</i> , 2011, 79, 1379-1380.	5.2	0
479	A 72-Year-Old Woman With Several Months of Weight Loss and Generalized Weakness. <i>American Journal of the Medical Sciences</i> , 2012, 344, 142-145.	1.1	0
480	Thiazide and Thiazide-Like Diuretics. <i>Hypertension</i> , 2012, 59, 1089-1090.	2.7	0
481	Obesity, blood pressure, and cardiovascular outcomes " Authors' reply. <i>Lancet, The</i> , 2013, 381, 1982-1983.	13.7	0
482	Benefits Improvement and Protection Act's Impact on Transplantation Rates Among Elderly MEDICARE Beneficiaries With End-Stage Renal Disease. <i>Transplantation</i> , 2013, 95, 463-469.	1.0	0
483	Effect of Canagliflozin (CANA) in Patients With Type 2 Diabetes Mellitus (T2DM) Based on Age and Estimated Glomerular Filtration Rate (eGFR). <i>Canadian Journal of Diabetes</i> , 2014, 38, S12.	0.8	0
484	Access to Kidney Transplantation: Is There a Potential Conflict of Interest?. <i>American Journal of Nephrology</i> , 2015, 41, 502-503.	3.1	0
485	The Authors Reply:. <i>Kidney International</i> , 2015, 87, 863-864.	5.2	0
486	Hematologic Complications of Chronic Kidney Disease. , 2015, , 277-284.		0

#	ARTICLE	IF	CITATIONS
487	Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study. <i>Transplantation Direct</i> , 2016, 2, e98.	1.6	0
488	OS 19-03 TREATMENT WITH PATIROMER RESULTED IN DECREASES IN ALDOSTERONE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA ON RAAS INHIBITORS. <i>Journal of Hypertension</i> , 2016, 34, e228-e229.	0.5	0
489	Biomarkers for Predicting Improved Outcomes With Renal Artery Stenting. <i>Hypertension</i> , 2016, 68, 1098-1099.	2.7	0
490	OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD. <i>Journal of Hypertension</i> , 2016, 34, e229.	0.5	0
491	Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error. <i>American Journal of Nephrology</i> , 2016, 44, 169-169.	3.1	0
492	TREATMENT WITH PATIROMER DECREASES ALDOSTERONE IN PATIENTS WITH HEART FAILURE, CHRONIC KIDNEY DISEASE, AND HYPERKALEMIA ON RAAS INHIBITORS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 912.	2.8	0
493	The Author Replies. <i>Kidney International</i> , 2017, 92, 1016-1017.	5.2	0
494	Inhibition of the Renin-Angiotensin System: How Far Have We Come?. , 2017, , 77-95.		0
495	Primary care of the kidney transplant recipient. , 2019, , 424-428.		0
496	Immunosuppression. , 2019, , 405-409.		0
497	SPO49INFLAMMATION AND APPARENT TREATMENT RESISTANT HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
498	Chronic Kidney Disease in the Primary Care Setting: Cardiovascular Disease Risk and Management. <i>Contemporary Cardiology</i> , 2019, , 179-216.	0.1	0
499	The authors reply. <i>Kidney International</i> , 2020, 97, 213-214.	5.2	0
500	BLOOD PRESSURE EFFECTS OVER TIME OF BIPOLAR RADIOFREQUENCY RENAL DENERVATION IN UNTREATED HYPERTENSION. <i>Journal of Hypertension</i> , 2021, 39, e10.	0.5	0
501	FC 024SAFETY AND EFFICACY OF PATIROMER FOR HYPERKALAEMIA IN PATIENTS WITH STAGE 1-3A OR STAGE 3B-5 CHRONIC KIDNEY DISEASE: POOLED ANALYSIS OF THE AMETHYST-DN, OPAL-HK AND TOURMALINE TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
502	FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
503	Antihypertensive therapy: Progression of Renal Injury. , 2003, , 209-240.		0
504	Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. , 2005, , 543-556.		0

#	ARTICLE	IF	CITATIONS
505	Chronic Kidney Disease in the Primary Care Setting: Importance for Estimating Cardiovascular Disease Risk and Use of Appropriate Therapies. , 2011, , 165-183.		0
506	Dual Blockade of the Renin-“Angiotensin”-Aldosterone System: Benefits Versus Adverse Outcomes. , 2012, , 453-465.		0
507	132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes, 2020, 69, 132-LB.	0.6	0
508	Clinical commentary: how to choose blood pressure goals and treatment: influence of estimated glomerular filtration rate and albuminuria. Transactions of the American Clinical and Climatological Association, 2008, 119, 53-61; discussion 61-3.	0.5	0
509	Hypertension in Elderly African-Americans. The American Journal of Geriatric Cardiology, 1997, 6, 13-20.	0.6	0
510	Recognition and Management of a Less Common Cause of Chronic Kidney Disease: Autosomal Dominant Polycystic Kidney Disease. Journal of Family Practice, 2020, 69, S57-S62.	0.2	0